Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

Inclusion Criteria

• •1. Aged 18-75 years old, both gender;
• •2. ECOG: 0-1;
• •3. Squamous non-small-cell lung cancer (stage IIIB or IV) confirmed by histologically or cytologically ;
• •4. No prior chemotherapy, biological therapy or immunotherapy; or subjects have recurrence and metastasis more than 6 months after the end of chemotherapy, but not gemcitabine or paclitaxel;
• •5. At least one radiographically measurable or assessable lesion on chest CG according to RECIST1.1 (response evaluation criteria of solid tumors); regional lymph node metastases may also be measured or assessed by imaging (mediastinal lymph nodes);
• •6. Life expectancy of at least 12 weeks;
• •7. Before treatment, blood tests or biochemical measurements must meet the following criteria:
• •* White blood cell count (WBC)≥ 4.0\*10\^9/L;
• •* Neutrophil count (ANC)≥ 2.0\*10\^9/L;
• •* Platelet count (PLT)≥ 100\*10\^9/L;
• •* Hemoglobin (Hb)≥ 100g/L;
• •* Hepatic function: serum bilirubin ≤ 1.5 times the upper normal limit,aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper normal limit;
• •* Renal function: creatinine ≤ 1.5 times the upper normal limit;
• •8. Signed informed consent.